WO2007044695A3 - ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF - Google Patents

ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF Download PDF

Info

Publication number
WO2007044695A3
WO2007044695A3 PCT/US2006/039463 US2006039463W WO2007044695A3 WO 2007044695 A3 WO2007044695 A3 WO 2007044695A3 US 2006039463 W US2006039463 W US 2006039463W WO 2007044695 A3 WO2007044695 A3 WO 2007044695A3
Authority
WO
WIPO (PCT)
Prior art keywords
sars
methods
cov
coronavirus
antibodies against
Prior art date
Application number
PCT/US2006/039463
Other languages
French (fr)
Other versions
WO2007044695A2 (en
Inventor
Wayne Marasco
Jianhua Sui
Original Assignee
Dana Farber Cancer Inst Inc
Wayne Marasco
Jianhua Sui
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Wayne Marasco, Jianhua Sui filed Critical Dana Farber Cancer Inst Inc
Publication of WO2007044695A2 publication Critical patent/WO2007044695A2/en
Publication of WO2007044695A3 publication Critical patent/WO2007044695A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides scFv antibodies and monoclonal antibodies that neutralize SARS-CoV. Also provided are methods of treating and/or preventing a coronavirus-related disease or disorder such as SARS. The invention also provides methods of vaccinating a patient against SARS-CoV. Also provided are methods of diagnosing coronavirus-related diseases or disorders and methods of detecting the presence of a coronavirus in a sample. The invention additionally provides methods of screening for compounds that modulate the binding of SARS-CoV and the SARS-CoV receptor ACE2 as well as for compounds useful to treat SARS-Co V-related diseases or disorders.
PCT/US2006/039463 2005-10-07 2006-10-10 ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF WO2007044695A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72513805P 2005-10-07 2005-10-07
US60/725,138 2005-10-07
US72576705P 2005-10-12 2005-10-12
US60/725,767 2005-10-12

Publications (2)

Publication Number Publication Date
WO2007044695A2 WO2007044695A2 (en) 2007-04-19
WO2007044695A3 true WO2007044695A3 (en) 2007-08-23

Family

ID=37836991

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/039463 WO2007044695A2 (en) 2005-10-07 2006-10-10 ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF

Country Status (1)

Country Link
WO (1) WO2007044695A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100115346A (en) 2007-12-06 2010-10-27 다나-파버 캔서 인스티튜트 인크. Antibodies against influenza virus and methods of use thereof
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2021202893A1 (en) * 2020-04-03 2021-10-07 Nonigenex, Inc. Detecting adaptive immunity to coronavirus
WO2021203034A2 (en) * 2020-04-03 2021-10-07 Firebreak, Inc. Alimentary and systemic antiviral therapeutics
WO2021207433A2 (en) * 2020-04-07 2021-10-14 The Regents Of The University Of California Epitopes of sars-cov-2 neutralizing antibodies
US20230374114A1 (en) * 2020-04-16 2023-11-23 Dana-Farber Cancer Institute, Inc. Coronavirus antibodies and methods of use thereof
WO2021214467A1 (en) * 2020-04-23 2021-10-28 Cellbio A diagnostic tool improvement comprising a pathogen binding molecule
WO2021216876A2 (en) * 2020-04-24 2021-10-28 The Board Of Regents Of The University Of Texas System Antibodies to coronavirus spike protein and methods of use thereof
WO2021231237A2 (en) * 2020-05-11 2021-11-18 Augmenta Bioworks, Inc. Antibodies for sars-cov-2 and uses thereof
WO2021239666A1 (en) * 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
WO2021252620A2 (en) * 2020-06-09 2021-12-16 The Wistar Institute Of Anatomy And Biology Dna encoded antibodies for use against sars-cov-2
WO2021254476A1 (en) * 2020-06-19 2021-12-23 南京金斯瑞生物科技有限公司 Magnetic microparticle chemiluminescence reagent kit for detecting sars-cov-2 virus neutralising antibodies and application therefor
CN113945714B (en) * 2020-07-16 2023-01-31 南京蓬勃生物科技有限公司 Method for detecting neutralizing capacity of novel coronavirus neutralizing antibody drugs
US11963955B2 (en) 2020-08-13 2024-04-23 Texas Southern University Compositions for and methods of inhibiting SARS-CoV2 infection
WO2022054068A1 (en) * 2020-09-14 2022-03-17 Ramot At Tel-Aviv University Ltd. Antibodies for the prevention, treatment and detection of coronavirus infection
EP3970798A1 (en) * 2020-09-18 2022-03-23 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Sars-cov-2-nanobodies
CN112409488B (en) * 2020-10-23 2022-07-01 中国科学院上海药物研究所 Monoclonal antibody aiming at various coronaviruses and application
CN114805570B (en) * 2021-01-27 2023-11-07 中国科学院微生物研究所 Anti-human ACE2 monoclonal antibody and application thereof
WO2022161346A1 (en) * 2021-01-27 2022-08-04 Bioduro (Jiangsu) Co., Ltd. Antibody against sars-cov-2
TW202309075A (en) * 2021-04-30 2023-03-01 美商亞得捷歐治療公司 Compounds specific to coronavirus s protein and uses thereof
IT202200008198A1 (en) * 2022-04-26 2023-10-26 Stefania Galdiero SENSOR FOR THE DETECTION OF VIRAL INFECTIONS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2006051091A1 (en) * 2004-11-11 2006-05-18 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060520A2 (en) * 2003-11-25 2005-07-07 Dana-Farber Cancer Institute, Inc. ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2006051091A1 (en) * 2004-11-11 2006-05-18 Crucell Holland B.V. Compositions against sars-coronavirus and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRINK VAN DEN E N ET AL: "MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF HUMAN MONOCLONAL ANTIBODIES BINDING TO THE SPIKE AND NUCLEOCAPSID PROTEINS OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 79, no. 3, February 2005 (2005-02-01), pages 1635 - 1644, XP009049268, ISSN: 0022-538X *

Also Published As

Publication number Publication date
WO2007044695A2 (en) 2007-04-19

Similar Documents

Publication Publication Date Title
WO2007044695A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2005060520A3 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2006138729A3 (en) Receptor antagonists for treatment of metastatic bone cancer
CL2007002800A1 (en) ANTI-RECEIVER MONOCLONAL ANTIBODY OF INTERLEUCINE 17 (IL-17RA) OR FRAGMENT OF ANTIGEN UNION OF THE SAME; POLINUCLEOTIDE THAT CODIFIES IT; PREPARATION METHOD; AND METHOD TO TREAT A DISORDER INFLUENCED BY THE ACTIVATION OF IL-17RA.
WO2007092433A3 (en) Osteoporosis associated markers and methods of use thereof
WO2008066691A3 (en) Tes7 and antibodies that bind thereto
WO2005121179A3 (en) Transferrin receptor antibodies
HK1074634A1 (en) Internalizing antibodies specific for the raag10 cell surface target
WO2006105081A3 (en) Pharmacokinetically improved compounds
WO2008153705A3 (en) Methods of treating, diagnosing and detecting fgf21-associated disorders
WO2005115453A3 (en) Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies
WO2007045927A3 (en) Therapeutic agent
WO2008025020A3 (en) Cd30 binding agents and uses thereof
WO2007073497A3 (en) Calcium channel antagonists
NZ595225A (en) Use of tnf inhibitor for treatment of erosive polyarthritis
WO2007011941A3 (en) Human anti-b7rp1 neutralizing antibodies
DE602004029399D1 (en)
WO2008082651A3 (en) Dual-specific il-1a/ il-1b antibodies
WO2006096487A3 (en) Methods and compositions for modulating tweak and fn14 activity
WO2006084078A3 (en) Jam-3 and antibodies that bind thereto
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
WO2007033230A3 (en) Anti-cd3 antibody formulations
WO2009088805A3 (en) Antibody targeting through a modular recognition domain
TW200714716A (en) Method
WO2007056457A3 (en) Methods, compositions, and kits for the treatment of medical conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06825661

Country of ref document: EP

Kind code of ref document: A2